Effects of acute and chronic desipramine treatment on somatostatin receptors in brain

The effects of acute (5 mg/kg, IP twice daily for 2 days) and chronic (5 mg/kg IP twice daily for 21 days) administration of desipramine (DMI) on [¹²⁵I]-Tyr¹¹-somatostatin binding sites in brain were examined. There was no change in [¹²⁵I]Tyr¹¹-somatostatin binding in membranes prepared from the frontal cortex, striatum, and hippocampus of rats acutely or chronically treated with DMI as compared to non treated animals. [¹²⁵I]Tyr¹¹-Somatostatin binding was increased in membranes prepared from the rat nucleus accumbens only after chronic DMI administration. Scatchard analysis of the binding data from the nucleus accumbens showed that [¹²⁵I]Tyr¹¹-somatostatin labels a single population of somatostatin binding sites with an affinity constant, K_d, of 1.8±0.60 nM and a B_max of 330±90 fmol/mg protein. Chronic treatment with DMI increased the B_max (500±140 fmol/mg protein) but had no effect on the K_d. This finding shows a regional effect of DMI on [¹²⁵I]Tyr¹¹-somatostatin binding sites in rat brain and suggests that somatostatin may play a role in the pathophysiology of depression.     

Ontogenetic Development of 5-HT1D Receptors in Human Brain: An Autoradiographic Study

The pattern of pre- and postnatal appearance of 5-HT_1D receptors throughout the different areas of the human brain was studied by quantitative in vitro autoradiography, using [¹²⁵I]GTI (serotonin O -carboxymethyl-glycyl-[¹²⁵I]tyrosinamide) as a ligand. The anatomical distribution of 5-HT_1D receptors in neonatal, infant and children's brain was in good agreement with that observed in the adult, the basal ganglia and substantia nigra being the most intensely labelled areas. The development of these receptors throughout the human brain was mainly postnatal: low densities of [¹²⁵I]GTI binding sites were observed at the fetal/neonatal stage in most regions analyzed, in contrast with the high levels of labelling found in infant and children's brains. Indeed, in a number of regions, including the globus pallidus, substantia nigra and visual cortex, a peak of overexpression of 5-HT_1D receptors was observed in the first decade of life. Such overexpression could support a regulatory role for 5-HT_1D receptors in advanced periods of the CNS developmental process. Our results also indicate that the administration of drugs acting on 5-HT_1D receptors during the early postnatal period of life could result in modifications of their properties, as these receptors are already functional in this period.     

卵巢甲状腺肿并发胸腹水及血清CA125升高1例报告

本文报告1例卵巢甲状腺肿并发胸腹水及血清CA125升高.     

CA125水平与肝硬化腹水定量及预后判断的关系探讨

目的探讨肝硬化患者CA125水平与腹水定量及预后的关系.方法肝硬化患者115例,84例伴有腹水,31例不伴有腹水;Child-pugh A级25例,B级53例,C级37例,健康对照组31例.用放射免疫法检测血清CA125水平,42例患者同时检测腹水CA125水平.对47例患者进行随访,其中25例有腹水,22例无腹水,结合CA125水平,观察腹水再发生的情况.结果肝硬化患者血清CA125显著高于正常对照组,并随肝硬化程度加重而进行性增加.伴有腹水患者血清CA125水平明显提高,与同一Child分级的无腹水患者相比有统计学意义.而且随着腹水量的增多,其血清CA125水平也呈逐渐升高趋势.CA125水平高且有腹水者腹水的再发生多,而CA125水平正常者腹水的再发生少.结论血清CA125水平对衡量肝硬化患者的预后和预测腹水再发生率有一定的参考价值.     

结核性胸水患者治疗前后检测血清CA125的临床价值

CA12 5在卵巢肿瘤诊断中已被广泛应用 ,并被证实对消化系统恶性肿瘤的诊断也有较好的参考价值 ;在胚胎组织发育中也可找到 ,属混合性肿瘤标志物[1 ] 。国外已有文献报道结核性腹膜炎患者血清CA12 5可明显升高[2 ] 。我们对结核性胸水患者血清CA12 5治疗前后水平的变化进行了临床分析。对象与方法1.对象 :3 6例均为我院收住院的结核性胸水患者 ,男性 2 1例 ,女性 15例 ,年龄 2 6～ 82岁 ,平均年龄 5 5岁± 13岁。依据陈灏珠主编的《实用内科学》第 10版的诊断标准确诊 ,并结合临床表现、X线胸片或CT、PPD试验 ,胸水ADA和抗结核治疗有效…     

手助腹腔镜胆肠、胃肠内引流术联合125I粒子置入术治疗晚期胰腺癌

目的探讨手助腹腔镜胆肠、胃肠内引流术联合125I粒子置入术治疗晚期胰腺癌的可行性和临床疗效. 方法2002年2月～2004年8月,我院行手助腹腔镜胆肠、胃肠内引流术联合125I粒子置入术治疗晚期胰腺癌12例(胰头癌10例,胰体癌2例). 结果 12例手术均获成功.手术时间104～181 min,(122±29) min.术中出血量45～152 ml,(60±18) ml.住院时间6～17 d,(8.5±1.3) d.术后病人黄疸逐渐减退,术后7～10 d肝功能恢复正常.腹痛消失3例,明显缓解7例.2例出现胃肠功能障碍,治疗后缓解.10例术后随访6个月复查CT肿瘤明显缩小(PR)4例,无变化(NC)4例,肿瘤进展(PD) 2例. 结论手助腹腔镜内引流术联合癌组织间125I粒子置入术是治疗晚期胰腺癌,使其缓解症状的有效方法,具有创伤小、恢复快、能改善病人生活质量.     

CA125测定对某些妇科肿瘤的诊断意义

本文对４０名正常妇女和２０２名妇科肿瘤、宫内膜异位症的患者进行了血清ＣＡ１２５的测定。结果表明９８％正常妇女血清ＣＡ１２５水平＜５０ｕ／ｍｌ，行经期水平高于滤泡期、黄体期和绝经期水平。五组妇科疾病患者血清ＣＡ１２５水平也进行了测定，并观察了２１名卵巢癌患者ＣＡ１２５水平的变化情况。卵巢癌患者ＣＡ１２５水平最高，它与其它疾病组及正常对照组有明显的差异。血清ＣＡ１２５的测定在妇科临床上是有价值的。     

D16S80和D16S125两位点RFLP在多囊肾症状前诊断中的应用

给出了用“混合型”雅可比级数的泰勒平均逼近黎普希兹函数类的点态估计。     

125~I－后标记检测DNA－蛋白质交联物的研究

１２５~Ｉ－后标记法是庄志雄等人（１９９４）提出的一种检测ＤＮＡ－蛋白质交联物（ＤＰＣｓ）的新技术，该法在检测离体ＣＨＯ细胞ＤＰＣｓ的实验中已显示出敏感、快速和简便的优点。本研究表明，１２５~Ｉ－后标记法不仅能有效地检出由紫外光和铬酸钾诱导的ＣＨＬ细胞ＤＰＣｓ，并能有效而敏感地检测由铬酸钾和氯化镍引起的大鼠不同组织特别是白细胞ＤＰＣｓ形成的情况，是一种敏感的和可考虑应用于人群调查的ＤＰＣｓ检测方法。